Just a moment, the page is loading...

*EISAI-E2080-G000-303




A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to Less Than 4 Years of Age With Inadequately Controlled Lennox-Gastaut Syndrome
rufinamide
E2080-G000-303
NCT01405053
EU CTR 2010-023505-36
Lennox-Gastaut Syndrome
Phase 3
 
No restrictions.
November 2017